European CHMP recommends paediatric license extension of budesonide / formoterol (BiResp Spiromax and DuoResp Spiromax) for treatment of asthma

The proposed license extension is for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate in adolescents (12 years and older).

Source:

European Medicines Agency